Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B
- 31 July 2005
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 43 (1) , 72-77
- https://doi.org/10.1016/j.jhep.2005.02.021
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver International, 2005
- Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis BJournal of Medical Virology, 2004
- Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?Journal of Hepatology, 2002
- Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology, 2001
- Evolution of Hepatitis B Virus Polymerase Gene Mutations in Hepatitis B E Antigen-Negative Patients Receiving Lamivudine TherapyHepatology, 2000
- Early Detection of Viral Resistance by Determination of Hepatitis B Virus Polymerase Mutations in Patients Treated by Lamivudine for Chronic Hepatitis BHepatology, 2000
- Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis BHepatology, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Selection of Mutations in the Hepatitis B Virus Polymerase During Therapy of Transplant Recipients With LamivudineHepatology, 1996
- Changes of serum HBV‐DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitisLiver International, 1988